quizartinib Articles
Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders
11 December 2012
Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug
6 November 2012
Acute myeloid leukemia market to be worth $1.67 billion by 2020
20 December 2011
Showing 1-4 of 4 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
